Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter
, Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin and Herrlinger, Ulrich
(2017)
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Neuro-Oncology 20 (7), pp. 975-985.
Date of publication of this fulltext: 28 Jul 2021 17:13
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Neuro-Oncology | ||||
| Publisher: | Oxford Univ. Press | ||||
|---|---|---|---|---|---|
| Place of Publication: | CARY | ||||
| Volume: | 20 | ||||
| Number of Issue or Book Chapter: | 7 | ||||
| Page Range: | pp. 975-985 | ||||
| Date | 2017 | ||||
| Institutions | Medicine > Lehrstuhl für Neurochirurgie | ||||
| Identification Number |
| ||||
| Keywords | MINI-MENTAL-STATE; ADJUVANT TEMOZOLOMIDE; PHASE-III; RADIOTHERAPY; CONCOMITANT; bevacizumab; crossover therapy; glioblastoma; progression; quality of life | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 47043 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric